Objective:

To investigate the specific role of CD276 in promoting sunitinib resistance in clear cell renal cell carcinoma.

Approach:

Key Findings:

• The article was retracted due to issues with data integrity, including a request for correction regarding a duplicated image in Fig. 3c.
• Discrepancies were found in the western blot scans and expected molecular weights.
• The authors could not provide adequate explanations or original raw data.

Interpretation:

The retraction indicates a significant lack of confidence in the validity of the research findings, raising concerns about data integrity in the field.

Limitations:

• Inability to verify the original data, which undermines the study's conclusions.
• Concerns over image duplication in published figures, affecting the credibility of the results.

Conclusion:

The article has been retracted by the editors, and all authors have agreed to this decision, reflecting a consensus on the issues identified.

Sources:

• BMC Cancer Retraction Notice
Source

Based on findings from:

Retraction Notice: The Role of CD276 in Promoting Sunitinib Resistance in Clear Cell Renal Cell Carcinoma Through DNA Damage Repair and FAK-MAPK Pathway Activation

Zhi-yu Zhang, Jian-hao Xu, Jiang-lei Zhang, Yu-xin Lin, Jun Ou-Yang. Bmc Cancer, 2026.

https://link.springer.com/article/10.1186/s12885-025-15511-z

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.